These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

339 related articles for article (PubMed ID: 25673122)

  • 1. Review of the efficacy and safety of fesoterodine for treating overactive bladder and urgency urinary incontinence in elderly patients.
    Wagg A; Oelke M; Angulo JC; Scholfield D; Arumi D
    Drugs Aging; 2015 Feb; 32(2):103-25. PubMed ID: 25673122
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Efficacy and tolerability of fesoterodine versus tolterodine in older and younger subjects with overactive bladder: a post hoc, pooled analysis from two placebo-controlled trials.
    DuBeau CE; Morrow JD; Kraus SR; Creanga D; Bavendam T
    Neurourol Urodyn; 2012 Nov; 31(8):1258-65. PubMed ID: 22907761
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Fesoterodine clinical efficacy and safety for the treatment of overactive bladder in relation to patient profiles: a systematic review.
    Chapple C; Oelke M; Kaplan SA; Scholfield D; Arumi D; Wagg AS
    Curr Med Res Opin; 2015 Jun; 31(6):1201-43. PubMed ID: 25798911
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Efficacy of fesoterodine compared with extended-release tolterodine in men and women with overactive bladder.
    Ginsberg D; Schneider T; Kelleher C; Van Kerrebroeck P; Swift S; Creanga D; Martire DL
    BJU Int; 2013 Aug; 112(3):373-85. PubMed ID: 23826844
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Economic impact of using fesoterodine for the treatment of overactive bladder with urge urinary incontinence in a vulnerable elderly population in the United States.
    Qin L; Luo X; Zou KH; Snedecor SJ
    J Med Econ; 2016; 19(3):229-35. PubMed ID: 26488196
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effect of fesoterodine in vulnerable elderly subjects with urgency incontinence: a double-blind, placebo controlled trial.
    Dubeau CE; Kraus SR; Griebling TL; Newman DK; Wyman JF; Johnson TM; Ouslander JG; Sun F; Gong J; Bavendam T
    J Urol; 2014 Feb; 191(2):395-404. PubMed ID: 23973522
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Characteristics of antimuscarinic responders versus suboptimal responders in a randomized clinical trial of patients with overactive bladder symptoms.
    Grenabo L; Herschorn S; Kaplan SA; Cardozo L; Scholfield D; Arumi D; Carlsson M; Chapman D; Ntanios F
    Curr Med Res Opin; 2017 Oct; 33(10):1731-1736. PubMed ID: 28758802
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparison of fesoterodine and tolterodine extended release for the treatment of overactive bladder: a head-to-head placebo-controlled trial.
    Herschorn S; Swift S; Guan Z; Carlsson M; Morrow JD; Brodsky M; Gong J
    BJU Int; 2010 Jan; 105(1):58-66. PubMed ID: 20132103
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparison of fesoterodine and tolterodine in patients with overactive bladder.
    Chapple CR; Van Kerrebroeck PE; Jünemann KP; Wang JT; Brodsky M
    BJU Int; 2008 Nov; 102(9):1128-32. PubMed ID: 18647298
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Superiority of fesoterodine 8 mg vs 4 mg in reducing urgency urinary incontinence episodes in patients with overactive bladder: results of the randomised, double-blind, placebo-controlled EIGHT trial.
    Chapple C; Schneider T; Haab F; Sun F; Whelan L; Scholfield D; Dragon E; Mangan E
    BJU Int; 2014 Sep; 114(3):418-26. PubMed ID: 24552358
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Long-term safety, tolerability and efficacy of flexible-dose fesoterodine in elderly patients with overactive bladder: open-label extension of the SOFIA trial.
    Wagg A; Khullar V; Michel MC; Oelke M; Darekar A; Bitoun CE
    Neurourol Urodyn; 2014 Jan; 33(1):106-14. PubMed ID: 23460503
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Fesoterodine: a new agent for treating overactive bladder.
    Ellsworth P; Berriman SJ; Brodsky M
    Am J Manag Care; 2009 Mar; 15(4 Suppl):S115-7. PubMed ID: 19355800
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Fesoterodine fumarate.
    Gomelsky A; Dmochowski RR
    Drugs Today (Barc); 2010 Feb; 46(2):81-90. PubMed ID: 20393636
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Safety and efficacy of fesoterodine fumarate in patients with overactive bladder: results of a post-marketing surveillance study in Korea.
    Kim TH; Lee SE; Lee HE; Lee KS
    Curr Med Res Opin; 2016 Aug; 32(8):1361-6. PubMed ID: 27046653
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Efficacy and safety of fesoterodine 8 mg in subjects with overactive bladder after a suboptimal response to tolterodine ER.
    Kaplan SA; Cardozo L; Herschorn S; Grenabo L; Carlsson M; Arumi D; Crook TJ; Whelan L; Scholfield D; Ntanios F;
    Int J Clin Pract; 2014 Sep; 68(9):1065-73. PubMed ID: 24898471
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Efficacy and safety of fesoterodine treatment for overactive bladder symptoms in elderly women with and without hypertension.
    Yokoyama O; Yamagami H; Hiro S; Hotta S; Yoshida M
    Int J Urol; 2018 Mar; 25(3):251-257. PubMed ID: 29224251
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Add-on fesoterodine for residual storage symptoms suggestive of overactive bladder in men receiving α-blocker treatment for lower urinary tract symptoms.
    Kaplan SA; Roehrborn CG; Gong J; Sun F; Guan Z
    BJU Int; 2012 Jun; 109(12):1831-40. PubMed ID: 21966995
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A pooled analysis of the efficacy of fesoterodine for the treatment of overactive bladder, and the relationship between safety, co-morbidity and polypharmacy in patients aged 65 years or older.
    Wagg A; Arumi D; Herschorn S; Angulo Cuesta J; Haab F; Ntanios F; Carlsson M; Oelke M
    Age Ageing; 2017 Jul; 46(4):620-626. PubMed ID: 28057620
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Does fesoterodine have a role in the treatment of poorly managed patients with overactive bladder?
    Morris V; Wagg A
    Drug Des Devel Ther; 2014; 8():113-9. PubMed ID: 24470751
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Multicriteria Decision Analysis Applied to the Clinical Use of Pharmacotherapy for Overactive Bladder Symptom Complex.
    Chapple CR; Mironska E; Wagg A; Milsom I; Diaz DC; Koelbl H; Pushkar D; Tubaro A; De Ridder D; Chartier-Kastler E; Phillips LD
    Eur Urol Focus; 2020 May; 6(3):522-530. PubMed ID: 31623981
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.